Sanofi, Regeneron reports cSCC data for PD-1 inhibitor cemiplimab

By Chris Lieu | Dec 15, 2017 | 5:09 PM GMT

Sanofi (Euronext:SAN; NYSE:SNY) and partner Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported top-line data from 82 evaluable patients with advanced cutaneous squamous cell carcinoma (cSCC) in the pivotal Phase II